

24 Lifesciences

**Diagnostic Imaging Clinical Trials Market
Regional Analysis, Demand Analysis and
Competitive Outlook 2025-2032**

Market Overview




Global diagnostic imaging clinical trials market size was valued at USD 1.19 billion in 2024. The market is projected to grow from USD 1.28 billion in 2025 to USD 1.93 billion by 2031, exhibiting a CAGR of 7.3% during the forecast period.

Diagnostic imaging clinical trials evaluate the efficacy of imaging modalities such as MRI, CT, ultrasound, and X-rays in disease detection and therapy monitoring. These trials are critical in determining optimal imaging protocols, improving diagnostic accuracy, and validating novel biomarkers for clinical use. The market encompasses radiological and non-radioactive imaging techniques deployed across hospitals, clinics, and research institutions.

Market size

MARKET INSIGHTS



2024

USD 1.19 billion in 2024

2032

USD 1.93 billion by 2031

CAGR

CAGR of 7.3%

<https://www.24lifesciences.co>

By Type

Radiological Imaging Diagnosis Segment Dominates the Market Due to its Precision in Disease Detection and Monitoring

The Diagnostic Imaging Clinical Trials market is segmented based on type into radiological and non-radioactive modalities, reflecting the diverse technologies employed in evaluating imaging efficacy for clinical endpoints. Radiological imaging, which includes techniques like X-rays, CT scans, and MRI, holds a leading position owing to its established role in providing high-resolution visuals essential for trial outcomes in oncology and cardiology studies. This segment's growth is fueled by ongoing advancements in hybrid imaging systems that enhance diagnostic accuracy. Non-radioactive imaging, encompassing ultrasound and optical methods, is gaining traction for its non-invasive nature and safety in longitudinal trials, particularly for pediatric and pregnant populations. These segments collectively drive market expansion by addressing the need for reliable, quantifiable data in therapeutic assessments.

- **Radiological Imaging Diagnosis**
- **Non-radioactive Imaging Diagnosis**

By Application



Hospital Segment Leads Due to Extensive Infrastructure and High-Volume Clinical Trial Participation

The market segmentation by application highlights the primary settings where diagnostic imaging trials are conducted, emphasizing the integration of imaging technologies into real-world healthcare environments. Hospitals dominate as they offer comprehensive facilities, multidisciplinary teams, and robust patient recruitment capabilities, making them ideal for large-scale Phase III trials that require advanced imaging endpoints. Clinics contribute by focusing on outpatient and community-based studies, providing cost-effective options for early-phase research and diverse population access. The 'Others' category includes specialized research centers and contract research organizations that support niche applications like decentralized trials. This segmentation underscores the market's adaptability to varying trial scales and the pivotal role of end-user environments in accelerating imaging innovation for better patient outcomes.

- Hospital**
- Clinic**
- Others**

Our Key Players

- ICON
- Parexel
- BioTelemetry
- ERT
- McLaren
- Bioclinica
- ProScan Imaging





**"Exclusive Analysis Inside:
Download the [2025] Report Now"**

<https://www.24lifesciences.com/download-sample/2749/minimally-invasive-fascial-suture-device-market-market>



<https://www.24lifesciences.com>



Connect with us.



Email

help@24lifesciences.com



Call us

+91 9425150513 (Asia)



Contact Us
City Vista ,Kharadi

<https://www.24lifesciences.com>